Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables (2016 - 2025)

Corcept Therapeutics' Receivables history spans 10 years, with the latest figure at $63.9 million for Q4 2025.

  • For Q4 2025, Receivables rose 10.0% year-over-year to $63.9 million; the TTM value through Dec 2025 reached $63.9 million, up 10.0%, while the annual FY2025 figure was $63.9 million, 10.0% up from the prior year.
  • Receivables for Q4 2025 was $63.9 million at Corcept Therapeutics, down from $73.5 million in the prior quarter.
  • Across five years, Receivables topped out at $80.0 million in Q1 2025 and bottomed at $23.9 million in Q1 2021.
  • The 5-year median for Receivables is $41.1 million (2023), against an average of $46.2 million.
  • The largest annual shift saw Receivables decreased 14.9% in 2021 before it skyrocketed 82.78% in 2024.
  • A 5-year view of Receivables shows it stood at $29.0 million in 2021, then rose by 13.2% to $32.9 million in 2022, then surged by 67.77% to $55.1 million in 2023, then rose by 5.36% to $58.1 million in 2024, then increased by 10.0% to $63.9 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Receivables are $63.9 million (Q4 2025), $73.5 million (Q3 2025), and $68.7 million (Q2 2025).